Enjoy complimentary customisation on priority with our Enterprise License!
The India contract research and manufacturing service (CRAMS) market size is estimated to grow by USD 14.08 million, at a CAGR of 10.8% between 2023 and 2028.
India's competitive advantage in offering cost-efficient solutions stems from various factors that contribute to lower operational expenses without compromising quality. Several prominent vendors exemplify India's prowess in providing cost-effective CRAMS solutions. Furthermore, the contract research and manufacturing service (CRAMS) market in India is characterized by its ability to offer a diverse range of services at cost-effective rates. These companies leverage India's regulatory expertise and cost advantages to deliver value-driven solutions to clients seeking regulatory approval for their products. Overall, the availability of cost-effective solutions for research, development, and manufacturing services in India positions the country as a preferred destination for outsourcing in the pharmaceutical and biotechnology sectors. These factors will drive the market during the forecast period.
To learn more about this report, Download Report Sample
In the realm of pharmaceutical and biotechnology industries, Contract Research and Manufacturing Services (CRAMS) play a pivotal role in accelerating drug discovery and development. Collaborating with Contract Research Organization (CROs), companies outsource critical tasks such as clinical trial data management, project management, and medicine and disease coding to optimize R&D pipelines. With a focus on precision/personalized medicine and decentralized clinical trials (DCT), CRAMS providers offer specialized re services including physical characterization and raw material testing to ensure safety and efficacy. As sponsors seek to minimize drug discovery and development costs, CRAMS continue to evolve, driving innovation and efficiency in the pharmaceutical landscape.
The market share growth by the manufacturing segment will be significant during the forecast period. CMOs are organizations that manufacture drugs and other pharmaceutical therapies, such as vaccines and healthcare products, on a contract basis for pharmaceutical vendors and biotechnology companies. Advances in medical sciences and the growing adoption of specialty medicines, along with other developments such as nanotechnology and stem cell research, are leading to the emergence of drugs that have a short half-life. These developments are creating demand for more composite manufacturing processes such as closed molding, open molding, and cast polymer molding.
Get a glance at the market contribution of various segments Download PDF Sample
The manufacturing segment was valued at USD 9.34 million in 2018. Further, the pharmaceutical industry in these countries is dominated by generic drug manufacturers, which also provide contract manufacturing services to various large pharmaceutical vendors across the globe. It is estimated that generic drug manufacturers outsource almost 80% of their production to CMOs. The services provided by CMOs primarily include bulk drug contract manufacturing of active pharmaceutical ingredients (APIs). Owing to these factors, the manufacturing segment of the contract research and manufacturing service (CRAMS) market in India is expected to witness significant growth during the forecast period.
The cardiovascular therapeutic area segment is a crucial part of the market, reflecting the countrys growing prominence in cardiovascular research, as well as the development and manufacturing of relevant therapeutics. Indian CROs and CMOs provide a wide range of services tailored to the needs of pharmaceutical companies and research institutions engaged in cardiovascular drug discovery and production. These services encompass preclinical and clinical research, regulatory support, formulation development, and commercial-scale manufacturing of cardiovascular drugs and therapeutics. With a skilled workforce, advanced infrastructure, and cost-effective solutions, India has emerged as a hub for outsourcing cardiovascular research and manufacturing activities, contributing significantly to the development of innovative treatments for cardiovascular diseases (CVDs) globally. Thus, such factors will drive the growth of the cardiovascular segment of the contract research and manufacturing service (CRAMS) market in India during the forecast period.
The infectious disease therapeutic area segment is a vital component of the market, reflecting the countrys expertise and capabilities in combating different infectious diseases. Indian CROs and CMOs offer a diverse range of services tailored to the needs of pharmaceutical companies, biotechnology firms, and government agencies engaged in infectious disease research and the development and manufacturing of related drugs and vaccines. These services encompass various aspects of infectious disease management, including drug and vaccine discovery, preclinical and clinical research, diagnostics development, and vaccine manufacturing. Thus, the segment underscores the significant role of companies in advancing research, development, and manufacturing of drugs for infectious diseases, positioning the country as a key player in the global fight against infectious diseases. Thus, such factors will drive market growth during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
Arch Pharmalabs Ltd., Aurobindo Pharma Ltd., BHAGWATI ORGANICS PVT. LTD., Biocon Ltd., Dhanuka Agritech Ltd., Dishman Carbogen Amcis Ltd., Divis Laboratories Ltd., Ind Swift Laboratories Ltd., Ipca Laboratories Ltd., Jubilant Pharmova Ltd., Lupin Ltd., Merck and Co. Inc., MSN Laboratories, Murli Krishna Pharma, Piramal Enterprises Ltd., Solara, Sun Pharmaceutical Industries Ltd., TCG Lifesciences Pvt. Ltd., and Wockhardt Ltd.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
In the dynamic pharmaceutical landscape, Contract Research and Manufacturing Services (CRAMS) stand as essential partners in drug development. Collaborating with CRO services, and academic institutes, CRAMS providers offer a spectrum of services encompassing research, database design, and data validation to bolster the R&D pipeline. Vital functions like patient recruitment and quality and metric reporting streamline the development pipeline, enhancing efficiency and expediting drug products to market. With a focus on safety and efficacy summaries, CRAMS ensure compliance while providing specialized services such as physical characterization services and raw material testing services. Outsourcing critical tasks, CRAMS remain integral to pharmaceutical innovation and progress. Our researchers analyzed the market research and growth data with 2023 as the base year, along with the key India contract research and manufacturing service (CRAMS) market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage.
A diverse range of service offerings by CRAMS providers is the key factor driving the market. The landscape of the CRAMS market in India is characterized by a comprehensive suite of services that span the entire drug development and manufacturing lifecycle, catering to the diverse needs of pharmaceutical, biotechnology, and medical device companies worldwide. One of the distinctive strengths of CRAMS providers in India is their ability to offer end-to-end solutions, from early-stage research and development to commercial manufacturing and regulatory support.
Furthermore, Ipca Laboratories Ltd, a leading Indian pharmaceutical company, has diversified its offerings to include CRAMS, such as API manufacturing, formulation development, and contract manufacturing. IPCA Laboratories' strong focus on quality and compliance, coupled with its manufacturing capabilities and regulatory approvals, make it a trusted partner for outsourcing manufacturing and development activities. Thus, such factors will drive the growth of the CRAMS market in India during the forecast period.
Technological advancements in CRAMS is the primary trend shaping the market. CRAMS providers in India are leveraging cutting-edge technologies to enhance efficiency, productivity, and quality across various stages of the drug development and manufacturing process. One notable area of technological advancement is in the field of process optimization and automation. Companies like Jubilant Pharmova Ltd. have implemented advanced automation systems and process optimization techniques to streamline manufacturing operations, minimize waste, and improve yield. These technological innovations not only enhance operational efficiency but also reduce production costs, making CRAMS more cost-effective for clients.
Furthermore, the adoption of digital technologies such as artificial intelligence (AI), machine learning (ML), and data analytics is revolutionizing the landscape of the CRAMS market in India. These technologies are being utilized for predictive modeling, virtual screening, and data-driven decision-making in drug discovery and development. Further, advancements in bioprocessing technologies are driving innovation in the biopharmaceutical CRAMS segment. Companies like Biocon Ltd are at the forefront of developing novel bioprocessing techniques, such as continuous manufacturing and single-use systems, to improve the efficiency and scalability of biopharmaceutical production. These technological advancements are expected to fuel the growth of the CRAMS market in India during the forecast period.
Higher concentration of CROs than CMOs is the major challenge that affects the market growth. The saturation of CROs leads to intense competition among service providers, resulting in price wars and margin erosion. For instance, in the pharmaceutical sector, where outsourcing is highly prevalent, the abundance of CROs over CMOs often leads to aggressive pricing strategies to secure contracts, squeezing profit margins for all players involved. This not only impacts the financial sustainability of individual companies but also discourages investment in innovation and infrastructure upgrades necessary for long-term growth.
Moreover, the proliferation of service providers in terms of the number of both CROs and CMOs creates challenges for them with regard to differentiation in services and value propositions. With numerous options available, clients may struggle to discern which providers are most suitable for them, leading to the commoditization of services. Thus, such factors will impede the growth of the CRAMS market in India during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Customer Landscape
The market forecasting report provides comprehensive data with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
In the expansive landscape of pharmaceutical research and development, Contract Research and Manufacturing Services (CRAMS) emerge as pivotal players, offering a comprehensive suite of solutions tailored to meet the evolving demands of drug pipelines. Partnering with entities like the Center for Artificial Intelligence and leveraging cutting-edge technologies such as artificial intelligence (AI), CRAMS providers facilitate breakthroughs in diverse therapeutic areas from infectious diseases to neurology. With expertise spanning clinical research services, laboratory services, and toxicology testing Services, CRAMS entities drive innovation in pharma R&D while delivering personalized treatments and advancing the frontier of medicine.
Further, the market encompasses a vast array of essential services for data management services, and pharmacokinetics/pharmacodynamics services, and expertise crucial for advancing pharmaceutical research and development. From database design and build to data entry and validation, CRAMS providers ensure the integrity and reliability of critical data throughout the drug development process. Statistical analysis plans and reports offer valuable insights into the efficacy and safety of treatments for various conditions, including chronic diseases, CVS disorders, and respiratory disorders like metabolic disorders/endocrinology, and immunological disorders.
Additionally, with expertise spanning preclinical services to early phase development services and personalized medicines, CRAMS entities drive innovation and efficiency in drug discovery and development. Consulting services provide strategic guidance, while specialized offerings such as toxicology testing services and analytical testing services ensure regulatory compliance and product quality. In essence, CRAMS play a vital role in shaping the future of pharmaceuticals, advancing treatments across a wide range of therapeutic areas.
Market Scope |
|
Report Coverage |
Details |
Page number |
156 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.8% |
Market growth 2024-2028 |
USD 14.08 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
9.6 |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Aragen Life Sciences Pvt. Ltd., Arch Pharmalabs Ltd., Aurobindo Pharma Ltd., BHAGWATI ORGANICS PVT. LTD., Biocon Ltd., Dhanuka Agritech Ltd., Dishman Carbogen Amcis Ltd., Divis Laboratories Ltd., Ind Swift Laboratories Ltd., Ipca Laboratories Ltd., Jubilant Pharmova Ltd., Lupin Ltd., Merck and Co. Inc., MSN Laboratories, Murli Krishna Pharma, Piramal Enterprises Ltd., Solara, Sun Pharmaceutical Industries Ltd., TCG Lifesciences Pvt. Ltd., and Wockhardt Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Service
7 Market Segmentation by Therapeutic Area
8 Market Segmentation by End-user
9 Customer Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.